Ben Stone

Ben Stone joined AnaptysBio in May 2022 to lead the company’s Corporate Development functions. Prior to joining AnaptysBio, Mr. Stone was an Operating Principal at Two River, where he co-founded and held interim senior leadership roles in 76Bio and IconoVir Bio. Previously, Ben led the Corporate Strategy function at Spark Therapeutics until its acquisition by Roche, and was a member of the Healthcare Investment Banking Group at Credit Suisse. Mr. Stone has earned a B.S. in Finance from the Wharton School of the University of Pennsylvania and a B.A. in International Studies from the University of Pennsylvania.